Published in Biomed Res Int on June 03, 2014
A versatile mathematical work-flow to explore how Cancer Stem Cell fate influences tumor progression. BMC Syst Biol (2015) 0.78
Vasculature Disruption Enhances Bacterial Targeting of Autochthonous Tumors. J Cancer (2015) 0.76
NK cells control breast cancer and related cancer stem cell hematological spread. Oncoimmunology (2017) 0.75
Clinical applications of mouse models for breast cancer engaging HER2/neu. Integr Cancer Sci Ther (2016) 0.75
Maternal Immunization: New Perspectives on Its Application Against Non-Infectious Related Diseases in Newborns. Vaccines (Basel) (2017) 0.75
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med (2000) 19.81
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature (2002) 19.77
Fibroblasts in cancer. Nat Rev Cancer (2006) 18.95
Marrow stromal cells as stem cells for nonhematopoietic tissues. Science (1997) 17.06
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 15.70
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature (2007) 15.20
Endogenous human microRNAs that suppress breast cancer metastasis. Nature (2008) 14.37
Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science (1994) 12.83
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med (2011) 12.45
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol (2004) 10.55
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res (2003) 9.92
Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell (2002) 9.36
Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol (2008) 9.25
Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol (2003) 8.61
Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol (2001) 7.43
Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw (2006) 7.19
Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. Cancer Cell (2010) 6.33
Adipose tissue remodeling and obesity. J Clin Invest (2011) 6.12
Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer (2006) 5.60
Mechanisms of suppression by suppressor T cells. Nat Immunol (2005) 5.52
Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst (2004) 5.39
Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes (2006) 5.25
Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res (2008) 4.95
The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science (2001) 4.89
Stat proteins and oncogenesis. J Clin Invest (2002) 4.79
Cancer stem cells: an evolving concept. Nat Rev Cancer (2012) 4.57
Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med (1999) 4.41
Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma. J Clin Oncol (2012) 4.28
CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest (2010) 4.22
Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res (2010) 4.15
Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst (2000) 4.09
Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood (2003) 3.47
Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity (2008) 3.36
The therapeutic promise of the cancer stem cell concept. J Clin Invest (2010) 3.26
High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev (2007) 3.23
Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res (2011) 3.18
A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One (2010) 3.14
Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond) (2005) 3.00
Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol (2013) 2.96
Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res (2011) 2.85
The Aurora kinase family in cell division and cancer. Biochim Biophys Acta (2008) 2.84
Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood (2006) 2.67
DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol (2000) 2.65
CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. J Immunol (2005) 2.63
Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest (2011) 2.62
CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res (2012) 2.50
Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther (2008) 2.50
Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology (2009) 2.45
Obesity and breast cancer. Oncology (Williston Park) (2011) 2.45
Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res (2007) 2.41
The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer (2013) 2.35
Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell (2012) 2.34
Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res (2008) 2.29
Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. J Dig Dis (2010) 2.28
Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms. Clin Cancer Res (2012) 2.24
Osteopontin-c is a selective marker of breast cancer. Int J Cancer (2008) 2.20
Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res (2007) 2.18
Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol (2001) 2.15
Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res (2004) 2.12
CCL2 (monocyte chemoattractant protein-1) and cancer. Semin Cancer Biol (2004) 2.11
Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res (2009) 2.09
Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev (2013) 2.05
In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature (2014) 2.05
Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res (2007) 2.03
The inflammation highway: metabolism accelerates inflammatory traffic in obesity. Immunol Rev (2012) 2.01
Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res (2007) 1.97
Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol (2006) 1.95
Concise review: role of mesenchymal stem cells in wound repair. Stem Cells Transl Med (2012) 1.92
Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. Clin Cancer Res (2013) 1.89
Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res Treat (2007) 1.86
Clinical outcome prediction by microRNAs in human cancer: a systematic review. J Natl Cancer Inst (2012) 1.85
Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. J Leukoc Biol (2009) 1.83
Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. PLoS One (2012) 1.82
miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat Cell Biol (2013) 1.79
Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta. J Immunol (2010) 1.76
Absence of signaling into CD4⁺ cells via C3aR and C5aR enables autoinductive TGF-β1 signaling and induction of Foxp3⁺ regulatory T cells. Nat Immunol (2012) 1.74
Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer Discov (2012) 1.71
Hypoxia-inducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis. J Clin Invest (2012) 1.71
Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer Res (2008) 1.67
2011: the immune hallmarks of cancer. Cancer Immunol Immunother (2011) 1.66
Paracrine and endocrine effects of adipose tissue on cancer development and progression. Endocr Rev (2011) 1.65
Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J Immunol (2008) 1.63
Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. Cancer Res (2010) 1.60
Angiomotin belongs to a novel protein family with conserved coiled-coil and PDZ binding domains. Gene (2002) 1.58
Human mesenchymal stem cells respond to native but not oxidized damage associated molecular pattern molecules from necrotic (tumor) material. Eur J Immunol (2011) 1.54
Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep (2007) 1.53
Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med (2010) 1.52
Signaling through C5a receptor and C3a receptor diminishes function of murine natural regulatory T cells. J Exp Med (2013) 1.48
Identification of Differentially Expressed MicroRNAs in Osteosarcoma. Sarcoma (2011) 1.48
Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin Cancer Res (2010) 1.48
MHC antigens and tumor escape from immune surveillance. Adv Cancer Res (2001) 1.45
Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-alpha and TGF-beta. J Cell Sci (2005) 1.39
Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res (2004) 1.38
HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis. Cancer Res (2011) 1.38
Molecular pathways: adiponectin and leptin signaling in cancer. Clin Cancer Res (2013) 1.37
MicroRNA-135a contributes to the development of portal vein tumor thrombus by promoting metastasis in hepatocellular carcinoma. J Hepatol (2011) 1.37
Molecular mechanisms of leptin and adiponectin in breast cancer. Eur J Cancer (2011) 1.36
Maternal embryonic leucine zipper kinase is upregulated and required in mammary tumor-initiating cells in vivo. Cancer Res (2010) 1.35
Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther (2006) 1.32